[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiesi SAS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100589931","real-word-study-of-the-de-novo-extended-release-tacrolimus-in-kidney-transplantation-using-an-artificial-intelligence-100589931",false,"NCT06960824","Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence","Real-word Study of the de NOVO Use of Once-daily Extended-release tacrolimuS (LCPT) in Kidney Transplantation Using an ARTificial Intelligence Prognostic System: a Multicenter Prospective Ob-servational Study","NOVOSTART","Inclusion Criteria:\n\n* Kidney recipients aged 18 years and older.\n* Kidney recipients were transplanted from living or deceased donors\n* Patients receiving Envarsus® \\[Life-Cycle Pharma Tacrolimus\\] within 24 hours of kidney transplantation in a once-daily formulation at the discretion of the investiga-tor and in compliance with the summary of product characteristics.\n* Patients are willing to participate in the study and do not oppose the use of their data.\n* Patients are either affiliated with or beneficiaries of a social security scheme.\n\nExclusion Criteria:\n\n* Contraindications to the use of Life-Cycle Pharma Tacrolimus (Envarsus®).\n* Pre-transplant desensitization.\n* ABO is incompatible with a living donor.\n* Combined transplant (e.g. kidney-heart transplant, kidney-liver transplant).\n* Previous bariatric (or bypass) surgery.\n* Gastrointestinal problems are likely to affect the absorption of the Life-Cycle Pharma Tacrolimus (Envarsus®).\n* Diagnosis of Parkinson's disease or any other neurological syndrome causing tremor.\n* Patients who are part of another clinical trial or in a period of exclusion from another clinical trial with a molecule under study.\n* Pregnant women or breastfeeding.\n* Patients under legal protection (guardianship, curatorship) or deprived of their liberty through judicial or administrative decisions.\n* Patients under State Medical Assistance.","ALL","18 Years",{"count":20,"type":21},165,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the clinical efficacy of the LCPT En-varsus \\[Life-Cycle Pharma Tacrolimus\\] initiated in de novo (Day 0 of transplantation) using the Biopsy Proven Acute Re-jection and iBox (full and abbreviated algo-rithms).",[25],"Chronic Renal Disease","NOT_YET_RECRUITING","2025-04-29",{"date":29,"type":30},"2025-05-07","ACTUAL",{"date":32,"type":21},"2025-05",{"date":34,"type":21},"2027-12-31",{"name":36,"class":37},"Chiesi SAS","INDUSTRY",""]